Any current/future new fundraising through debt or equity?

The company is undertaking its largest-ever capex, with multiple projects extending up to December next year. They plan to fund the capex using roughly a 2:1 debt-to-equity ratio. Around ₹70 crore of loan is anticipated for this capex. Interest rate on loans could be around 4-5% if converted to foreign currency loans; otherwise, 9-10% in Indian Rupees. No specific mention of new equity fundraising; focus is on debt financing combined with equity. The company emphasizes they are not extensively extending equity, aiming to maintain reasonable return on equity. Management is confident about achie

Any current/future capex/capital investment/strategic investment?

Ongoing and upcoming capex includes expansion of specialty chemicals, intermediates for pharma and agrochemicals, and bulk chemicals. Large investment at Dahej to create a second site similar in size to the Roha plant, including multipurpose and dedicated plants. Capex includes a 50 crore investment in a sulphuric acid plant supporting both internal consumption (50%) and external sales (50%). Additional investments include about 10 crore for two multipurpose plants (total), 20 crore in recently developed intermediate products, and debottlenecking to expand production at Roha. The capex

Future growth expectations in sales/revenue/volumes?

The company expects growth driven by expansion into specialty chemicals, including pharmaceuticals, agrochemicals, pigments, dyes, paints, and coatings sectors. New and existing products, especially in specialty chemicals, are anticipated to scale up with increased traction, despite slower-than-expected initial growth due to COVID-related delays. Domestic and overseas markets have returned to pre-COVID normalcy, with reasonable demand and operating revenues. Planned debottlenecking at Roha will expand production of specialty products, adding to specialty revenue without drastically changing su

Future growth expectations in earnings/operating earnings/profits/EPS?

Company expects growth driven by ramp-up of existing specialty chemical products and new dedicated plants. Domestic and international markets showing signs of returning to pre-COVID levels, supporting revenue growth. Expansion capex aimed at specialty intermediates and custom synthesis with planned investments at Roha and Dahej sites. Anticipated 2x revenue generation from new intermediate projects with similar margin profiles as sulfones. Bulk chemical margins expected to remain lower than specialty chemical margins; overall gross margins stable. Growth in mature products expected if market n

DMCC Speciality Chemicals LtdQ2 FY21Chemicals & Petrochemicals

DMCC Speciality Chemicals Ltd Q2 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹294.7P/E: 18.4Market Cap: ₹734 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company expects growth driven by expansion into specialty chemicals, including pharmaceuticals, agrochemicals, pigments, dyes, paints, and coatings sectors.
New and existing products, especially in specialty chemicals, are anticipated to scale up with increased traction, despite slower-than-expected initial growth due to COVID-related delays.
Domestic and overseas markets have returned to pre-COVID normalcy, with reasonable demand and operating revenues.
Planned debottlenecking at Roha will expand production of specialty products, adding to specialty revenue without drastically changing sulfuric acid sales.
Long-term demand for sulfones (thermal paper coatings) is expected to return once normal activities (stadiums, cinemas, airlines) resume.
Capex investments aim for roughly 2x revenue from new plants, with a mix of dedicated and multipurpose facilities.
New projects expected to be commercial and improve cash flows and return ratios fully by FY23, assuming no disruptions.
Overall, growth is driven by product expansion, capacity utilization, and targeted investments in higher-value specialty chemicals.

Margin guidance

Category 3

Company expects growth driven by ramp-up of existing specialty chemical products and new dedicated plants.
Domestic and international markets showing signs of returning to pre-COVID levels, supporting revenue growth.
Expansion capex aimed at specialty intermediates and custom synthesis with planned investments at Roha and Dahej sites.
Anticipated 2x revenue generation from new intermediate projects with similar margin profiles as sulfones.
Bulk chemical margins expected to remain lower than specialty chemical margins; overall gross margins stable.
Growth in mature products expected if market normalcy continues.
No major new investments planned in bulk chemicals beyond current projects; focus on specialty chemicals.
Profitability may improve as new plants stabilize and optimize production.
External uncertainties remain (pandemic waves, commodity price fluctuations) which can impact near-term outlook.

See what DMCC Speciality Chemicals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company is undertaking its largest-ever capex, with multiple projects extending up to December next year.
They plan to fund the capex using roughly a 2:1 debt-to-equity ratio.
Around ₹70 crore of loan is anticipated for this capex.
Interest rate on loans could be around 4-5% if converted to foreign currency loans; otherwise, 9-10% in Indian Rupees.
No specific mention of new equity fundraising; focus is on debt financing combined with equity.
The company emphasizes they are not extensively extending equity, aiming to maintain reasonable return on equity.
Management is confident about achieving planned cash flows from ongoing projects.

Order book

The document does not explicitly mention the current or expected order book or pending orders for Dharamsi Morarji Chemical Company Limited. However, relevant insights inferred are: - The company has ongoing discussions and agreements with clients for dedicated specialty chemical plants, indicating confirmed orders or contracts. - There is reasonable confidence expressed by management in achieving planned cash flows from current projects based on customer discussions and existing supply. - The company continues investing in R&D and has products at various development stages, suggesting a pipeline but no quantified order backlog. - Demand from overseas and domestic markets is returning to pre-COVID levels, implying positive order inflow. - No precise figures or definite pending order backlog data are disclosed in the provided transcript.

See what DMCC Speciality Chemicals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Ongoing and upcoming capex includes expansion of specialty chemicals, intermediates for pharma and agrochemicals, and bulk chemicals.
Large investment at Dahej to create a second site similar in size to the Roha plant, including multipurpose and dedicated plants.
Capex includes a 50 crore investment in a sulphuric acid plant supporting both internal consumption (50%) and external sales (50%).
Additional investments include about 10 crore for two multipurpose plants (total), 20 crore in recently developed intermediate products, and debottlenecking to expand production at Roha.
The capex is the largest in the company's history, estimated to generate approximately 200 crore in revenue per 100 crore investment once plants run at full capacity.
Planned maintenance shutdown and restructuring have impacted recent operations; new investments signal a strategic growth phase.
Financing planned at a ~2:1 debt-to-equity ratio; options include foreign currency loans at 4-5% or INR loans at 9-10%.
Continued R&D investments for globally competitive processes and development of new products are ongoing.

Track DMCC Speciality Chemicals Ltd — get its next earnings analysis in your feed

How does DMCC Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisDMCC Speciality Chemicals Ltd

Rev 3Mar 3

See where DMCC Speciality Chemicals Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does DMCC Speciality Chemicals Ltd rank in Chemicals & Petrochemicals?

Compare DMCC Speciality Chemicals Ltd against every Chemicals & Petrochemicals company (Q2 FY21) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What DMCC Speciality Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

POCL Enterprises Ltd (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
Deepak Nitrite Ltd (Q2 FY27)
Q2 FY27 total revenue: ₹3,091 crore, up 61% YoY (Page 1, 4, 5, 6, 10, 11) . Key investor presentation takeaways from Deepak Nitrite Ltd's Q2 FY27 investor prese
Privi Speciality Chemicals Ltd (Q2 FY27)
19,239.47 lakhs (approximately 33.9% growth). Key results statement takeaways from Privi Speciality Chemicals Ltd's Q2 FY27 results statement — and how it ranks
NOCIL Ltd (Q2 FY27)
427 crores . Key investor presentation takeaways from NOCIL Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

DMCC Speciality Chemicals Ltd Q2 FY21 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does DMCC Speciality Chemicals Ltd rank in Chemicals & Petrochemicals?

Continue your research

What DMCC Speciality Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season